AU2003247141A8 - 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases - Google Patents

4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases

Info

Publication number
AU2003247141A8
AU2003247141A8 AU2003247141A AU2003247141A AU2003247141A8 AU 2003247141 A8 AU2003247141 A8 AU 2003247141A8 AU 2003247141 A AU2003247141 A AU 2003247141A AU 2003247141 A AU2003247141 A AU 2003247141A AU 2003247141 A8 AU2003247141 A8 AU 2003247141A8
Authority
AU
Australia
Prior art keywords
anilido
inhibitors
growth factor
factor receptor
epidermal growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003247141A
Other versions
AU2003247141A1 (en
Inventor
Alexander Levitzki
Aviv Gazit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2003247141A1 publication Critical patent/AU2003247141A1/en
Publication of AU2003247141A8 publication Critical patent/AU2003247141A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003247141A 2002-08-01 2003-07-31 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases Abandoned AU2003247141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39973602P 2002-08-01 2002-08-01
US60/399,736 2002-08-01
PCT/IL2003/000632 WO2004013091A2 (en) 2002-08-01 2003-07-31 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases

Publications (2)

Publication Number Publication Date
AU2003247141A1 AU2003247141A1 (en) 2004-02-23
AU2003247141A8 true AU2003247141A8 (en) 2004-02-23

Family

ID=31495765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003247141A Abandoned AU2003247141A1 (en) 2002-08-01 2003-07-31 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases

Country Status (2)

Country Link
AU (1) AU2003247141A1 (en)
WO (1) WO2004013091A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
RU2370494C2 (en) 2003-09-19 2009-10-20 Астразенека Аб Quinazoline derivatives
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
BRPI0400869B8 (en) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp new compounds derived from 4-anilinoquinazolines with adenosine kinase inhibiting property
WO2006021881A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP2710006A1 (en) 2011-05-17 2014-03-26 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
CN102786512A (en) * 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-aryl unsaturated fused ring tertiary amine compound, preparation method thereof and application thereof to tumor resistance
US9394261B2 (en) 2012-09-14 2016-07-19 National Yang-Ming University Aryl amine substituted pyrimidine and quinazoline and their use as anticancer drugs
TW201427958A (en) * 2012-09-14 2014-07-16 Univ Nat Yang Ming Aryl amine substituted pyrimidine and quinazoline and their use as anticancer drugs
EA028614B1 (en) 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer
CN105732357A (en) * 2016-03-23 2016-07-06 叶芳 2-chloro-4-fluorobenzoic acid and preparation method thereof
CN110372666B (en) * 2018-04-13 2022-11-08 华东理工大学 Quinazoline compound as EGFR (epidermal growth factor receptor) triple mutation inhibitor and application thereof
JP2022501344A (en) * 2018-09-21 2022-01-06 スペクトラム ファーマシューティカルズ インコーポレイテッド New quinazoline EGFR inhibitor
CN114436975B (en) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-trifluoromethyl-4-aminoquinazoline compound and application thereof
CN114805223B (en) * 2022-05-30 2023-05-09 自贡市第四人民医院(自贡市急救中心) 2, 4-disubstituted quinazoline compound for inhibiting EGFR, preparation method and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases

Also Published As

Publication number Publication date
AU2003247141A1 (en) 2004-02-23
WO2004013091A3 (en) 2004-07-29
WO2004013091A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
HK1160859A1 (en) Inhibitors of tyrosine kinases
IL281945A (en) Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2003247141A8 (en) 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
HK1076598A1 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HK1077057A1 (en) Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
IL161921A0 (en) 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
EP1534290A4 (en) Novel inhibitors of kinases
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
EP1656378A4 (en) Compounds and compositions as inhibitors of receptor tyrosine kinase activity
IL161576A0 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
HK1091480A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL182584A0 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
IL182525A0 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
EP1594504A4 (en) Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
AU2001277524A1 (en) Novel use of inhibitors of the epidermal growth factor receptor
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1773367A4 (en) Epidermal growth factor receptor antagonists and methods of use
ZA200500414B (en) Process for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
AU2003276351A1 (en) Use of specific inhibitors of tyrosine kinases for immunomodulation
AU2003280250A8 (en) Crystal structures of bacterial thymidylate kinases
ZA200500492B (en) Novel inhibitors of kinases